Total Reports
19
Below-median volume
Breed profile · FDA CVM July 2026 extract
Adverse-event filings for Missouri Fox Trotting Horse (Horse) in the FDA Center for Veterinary Medicine openFDA extract. Browse horse breeds, reactions, and outcomes below.
By recorded gender -- every report on file for Missouri Fox Trotting Horse, no filtering.
Data updated September 2026
The verdict
According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Missouri Fox Trotting Horse ranks #364 of 510 by total reports (19). Death-coded-share rank requires at least 50 reports. National dual: Retriever - Labrador is #1 of 510 by total adverse-event reports (93,675) at death-coded-share rank 195 of 275 breeds with at least 50 reports (3.7%); separately, Atlantic Salmon (Salmo salar) is #1 highest death-coded share at 99.0% (report rank #233).
Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.
Release-over-release change
PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Missouri Fox Trotting Horse has 19 reports now versus 19 in that prior snapshot: 0 the same number of (0.0%).
This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.
Subscribe to Missouri Fox Trotting Horse changesTotal Reports
19
Below-median volume
Deaths Reported
1
of 19 reports
Death-coded share of reports
5.3%
5.3% death-coded
Avg Age at Report
20.1 yr
452.4 kg avg weight
5.3% of 19 missouri fox trotting horse reports involved a death outcome.
Read alongside breed popularity, veterinary access, and owner awareness, these shape how many events ever reach the FDA. The comparison line marks the cross-breed median death-coded share (4.8%) among breeds with 50 or more reports; values above it suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.
| Year | Reports | Trend |
|---|---|---|
| 2013 | 2 | |
| 2014 | 2 | |
| 2015 | 2 | |
| 2016 | 2 | |
| 2017 | 2 | |
| 2018 | 1 | |
| 2020 | 1 | |
| 2021 | 1 | |
| 2022 | 1 | |
| 2024 | 1 | |
| 2025 | 4 | |
Signature read: 19 reports place Missouri Fox Trotting Horse in the lower third of breed filing volume (#371 of 510). According to FDA CVM filings indexed on PlainBreed as of July 2026 extract, Missouri Fox Trotting Horse sits at #371 of 510 by report volume among all breeds and #40 of 55 among horse breeds, with 19 reports and 1 (5.3%) death-coded. Mean age at report: 20.1 years, average weight 452.4 kg (997.5 lbs).
Top reported signs: Diarrhoea (5), Lethargy (see also Central nervous system depression in 'Neurological') (5), Uncoded sign (2). Most-referenced drug: Pergolide Mesylate (8 reports), followed by Moxidectin (2) and Ivermectin(1.55%)/Praziquantel(7.75%) Paste (1).
Outcome coding on 19 status-recorded reports is dominated by Outcome Unknown (47.4%). Annual submissions ranged 1-2,025 across 11 years on file.
Showing 6 of 54 horse breeds in our dataset, ranked by closest report volume.
Sparse-volume peer sets for Missouri Fox Trotting Horse drawn from openFDA outside the Horse family so the neighborhoods are not species containment (the similar-volume list above stays within species).
Nearest other-species breeds by reported average weight (452.4 kg here).
What to do with this horse
A report does not prove a drug caused the reaction, and popular breeds simply generate more reports.
Compare a breed's report volume against how common the breed is before drawing conclusions. See our methodology for how the death-coded share and rankings are computed, or read breed-specific reporting patterns and FDA CVM reporting.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →